@JohnnyBlue I think your thinking of this from April:KAZIA...

@JohnnyBlue I think your thinking of this from April:

KAZIA PRESENTS PHARMACOKINETIC DATA FROM PAXALISIB PHASE II STUDY AT AACR ANNUAL MEETING

Interim analyses of efficacy data from this study have previously shown encouraging signals
of clinical efficacy, with a median overall survival (OS) of 17.5 months and a median
progression-free survival (PFS) of 8.4 months reported at the most recent data cut. These
figures compare very favourably to historical controls for temozolomide, which provide an
OS of 12.7 months and a PFS of 5.3 months.

The phase II study remains ongoing, with a number of patients in follow-up, and is expected
to deliver final data in 2H CY2021.